November 12, 2023
1 min watch
Save
VIDEO: Syfovre demonstrates ‘increasing effects’ at 3 years in geographic atrophy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Cedric Francois, MD, PhD, CEO of Apellis Pharmaceuticals, previews 3-year data investigating long-term treatment of geographic atrophy with Syfovre.
Results showed “increasing effects over time” with Syfovre (pegcetacoplan injection) as well as “slow downs up to 40% in the third year with multi-dosing,” Francois explained.
“This is something that we think will really be of great benefit to patients,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Francois C. Apellis. Presented at: Eyecelerator@AAO; Nov. 2, 2023; San Francisco.
Disclosures:
Francois reports being the CEO of Apellis.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.